Natera (NASDAQ:NTRA) Director Gail Boxer Marcus Sells 122 Shares

Natera, Inc. (NASDAQ:NTRA) Director Gail Boxer Marcus sold 122 shares of the business’s stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $198.71, for a total value of $24,242.62. Following the completion of the sale, the director owned 5,762 shares of the company’s stock, valued at approximately $1,144,967.02. This represents a 2.07% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Natera Trading Down 0.9%

Shares of NASDAQ NTRA opened at $196.45 on Wednesday. Natera, Inc. has a twelve month low of $122.08 and a twelve month high of $203.23. The stock has a 50 day moving average of $175.77 and a two-hundred day moving average of $162.77. The stock has a market cap of $26.96 billion, a P/E ratio of -102.85 and a beta of 1.75.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.14). Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The firm had revenue of $546.60 million during the quarter, compared to analysts’ expectations of $476.84 million. During the same quarter in the prior year, the firm posted ($0.30) EPS. Natera’s quarterly revenue was up 32.2% compared to the same quarter last year. Natera has set its FY 2025 guidance at EPS. As a group, research analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Guided Capital Wealth Management LLC grew its holdings in Natera by 0.5% during the second quarter. Guided Capital Wealth Management LLC now owns 13,135 shares of the medical research company’s stock worth $2,219,000 after acquiring an additional 66 shares during the period. Main Management ETF Advisors LLC grew its holdings in Natera by 1.7% during the second quarter. Main Management ETF Advisors LLC now owns 4,398 shares of the medical research company’s stock worth $743,000 after acquiring an additional 72 shares during the period. Yousif Capital Management LLC grew its holdings in Natera by 4.5% during the third quarter. Yousif Capital Management LLC now owns 1,682 shares of the medical research company’s stock worth $271,000 after acquiring an additional 72 shares during the period. Wedmont Private Capital grew its holdings in Natera by 4.9% during the second quarter. Wedmont Private Capital now owns 1,580 shares of the medical research company’s stock worth $256,000 after acquiring an additional 74 shares during the period. Finally, Gries Financial LLC grew its holdings in Natera by 4.0% during the third quarter. Gries Financial LLC now owns 1,904 shares of the medical research company’s stock worth $306,000 after acquiring an additional 74 shares during the period. Institutional investors and hedge funds own 99.90% of the company’s stock.

Wall Street Analysts Forecast Growth

NTRA has been the topic of a number of recent research reports. Cowen reissued a “buy” rating on shares of Natera in a report on Friday, August 8th. BNP Paribas Exane raised Natera from an “underperform” rating to a “neutral” rating and set a $172.00 target price on the stock in a report on Monday, October 27th. Morgan Stanley reissued an “overweight” rating and issued a $195.00 target price on shares of Natera in a report on Sunday, August 10th. Barclays reissued an “overweight” rating and issued a $210.00 target price (up previously from $190.00) on shares of Natera in a report on Friday, August 8th. Finally, Piper Sandler reissued an “overweight” rating and issued a $220.00 target price (up previously from $210.00) on shares of Natera in a report on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Natera currently has an average rating of “Moderate Buy” and an average price target of $194.89.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.